NASDAQ:CERO CERo Therapeutics (CERO) Stock Price, News & Analysis $0.53 +0.00 (+0.57%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CERo Therapeutics Stock (NASDAQ:CERO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CERo Therapeutics alerts:Sign Up Key Stats Today's Range$0.52▼$0.5450-Day Range$0.53▼$1.1152-Week Range$0.49▼$109.00Volume193,278 shsAverage Volume797,387 shsMarket Capitalization$2.85 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Read More… CERo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCERO MarketRank™: CERo Therapeutics scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCERo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCERo Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about CERo Therapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.84% of the float of CERo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCERo Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CERo Therapeutics has recently increased by 229.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCERo Therapeutics does not currently pay a dividend.Dividend GrowthCERo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted26.84% of the float of CERo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCERo Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CERo Therapeutics has recently increased by 229.78%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.48 News SentimentCERo Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CERo Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for CERO on MarketBeat in the last 30 days. MarketBeat Follows6 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CERo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.72% of the stock of CERo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.64% of the stock of CERo Therapeutics is held by institutions.Read more about CERo Therapeutics' insider trading history. Receive CERO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CERo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CERO Stock News HeadlinesMaxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy RecommendationMay 20 at 8:30 AM | msn.comMaxim Group Begins Coverage on CERo Therapeutics (NASDAQ:CERO)May 20 at 2:11 AM | americanbankingnews.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.May 23, 2025 | American Alternative (Ad)CERo Therapeutics (NASDAQ:CERO) Stock Price Up 1.5% - Here's What HappenedMay 16, 2025 | americanbankingnews.comCERo Therapeutics regains Nasdaq compliance, eyes trialsMay 9, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)May 8, 2025 | investing.comCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)May 8, 2025 | globenewswire.comCERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid LeukemiaMay 3, 2025 | nasdaq.comSee More Headlines CERO Stock Analysis - Frequently Asked Questions How have CERO shares performed this year? CERo Therapeutics' stock was trading at $6.00 at the beginning of 2025. Since then, CERO stock has decreased by 91.2% and is now trading at $0.5280. View the best growth stocks for 2025 here. How were CERo Therapeutics' earnings last quarter? CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) posted its earnings results on Thursday, May, 15th. The company reported ($1.59) earnings per share for the quarter. When did CERo Therapeutics' stock split? Shares of CERo Therapeutics reverse split on Wednesday, January 8th 2025. The 1-100 reverse split was announced on Monday, January 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are CERo Therapeutics' major shareholders? Top institutional shareholders of CERo Therapeutics include Armistice Capital LLC (5.80%), Parallel Advisors LLC (7.26%) and Avantax Planning Partners Inc. (2.45%). Insiders that own company stock include Stuart M Sloan and Bioventures Opportunities G Yk. View institutional ownership trends. How do I buy shares of CERo Therapeutics? Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CERo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI). Company Calendar Last Earnings5/15/2025Today5/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CERO Previous SymbolNASDAQ:CERO CIK1870404 Webwww.cero.bio Phone215-731-9450FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$11.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,233.3%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-108.43% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($259.05) per share Price / Book0.00Miscellaneous Outstanding Shares5,381,000Free Float2,485,000Market Cap$2.83 million OptionableN/A Beta0.66 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CERO) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.